| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch [K. S., J. J. W-P., J. H. T., K. K. H., M. E. L.], Laboratory of Pathophysiology [S. M. S.], Laboratory of Pathology [T. J. T.], and Laboratory of Viral Carcinogenesis [S. J. O.], National Cancer Institute, NIH, Bethesda, Maryland 20205
The MCF-7 human breast cancer cell line and four derived variant sublines (R27, R3, R3–12, and R3–98), which were all estrogen receptor positive, as well as the receptor-deficient line, MDA-MB-231, were compared both in vitro and as heterotransplants into athymic nude mice. The cell lines and heterotransplanted tumors were evaluated in terms of growth, receptor status, morphology by light and electron microscopy, karyotype, and allozyme phenotype analyses.
The R3 and R3–12 variant lines exhibited markedly retarded growth rates in vitro as compared with those of the MCF-7 parent line. The R3-12 line, which had the slowest growth rate in vitro as compared to those of the other cell lines, failed to produce tumors in nude mice after many attempts using various concentrations of tumor cell inocula. The MCF-7 and derived lines would not grow in oophorectomized animals without 17ß-estradiol replacement, with one rare exception, while the MDA-MB-231 receptor-deficient line was able to grow in oophorectomized mice with and without 17ß-estradiol replacement. Compared to the parent MCF-7 and R27 line in vivo and in vitro, the R3 line and its subclones had reduced progesterone receptor markedly.
By light microscopy, all of the cell lines in vivo and in vitro could be identified as adenocarcinoma. Using electron microscopy, the MCF and variant lines showed better tissue organization and more squamous features in vivo than in vitro where glandular features were more prominent. The R27 line in vivo and in vitro showed the most cellular polarity and differentiation as compared to the MCF or R3 lines (R3, R3–12, and R3–98), while the R3 lines were the least differentiated of all the lines. The MDA-MB-231 line in vivo and in vitro had the most pronounced glandular features of all the lines and was not affected by changes in media additions of fetal calf serum, 17ß-estradiol, or charcoal-treated calf serum as were the MCF-7- and MCF-7-derived lines.
All the tumors in vivo and in vitro showed a human karyotype, and the MCF-7 and each of the derived lines showed both common and unique chromosome markers.
The original cell line (MCF-7), the derived sublines (R27 and R3), and tumors derived in nude mice from these lines were typed for species identity using standard isozyme procedures and were found to be human. The allozyme phenotype at seven polymorphic human loci (allozyme genetic signature) demonstrated that the MCF-7 line and its derivatives were derived from the same individual and were distinct from the signatures of HeLa and a variety of other human breast cancer lines.
This multifaceted study, using both in vivo and in vitro systems, may provide a model for better understanding the nature of tumor heterogeneity and its implications in therapeutic designs.
1 To whom requests for reprints should be addressed, at Room 12C205, Building 10, National Cancer Institute, Bethesda, Md. 20205.
Received 6/24/82. Accepted 1/ 4/83.
This article has been cited by other articles:
|
|
 |
|
  P. A. Foster, S. K. Chander, S. P. Newman, L.W. L. Woo, O. B. Sutcliffe, C. Bubert, D. Zhou, S. Chen, B. V.L. Potter, M. J. Reed, et al. A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor Clin. Cancer Res., October 15, 2008; 14(20): 6469 - 6477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Foster, L. W. L. Woo, B. V. L. Potter, M. J. Reed, and A. Purohit The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against Hormone-Dependent Endometrial Cancer Endocrinology, August 1, 2008; 149(8): 4035 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Eckstein, K. Servan, L. Girard, D. Cai, G. von Jonquieres, U. Jaehde, M. U. Kassack, A. F. Gazdar, J. D. Minna, and H.-D. Royer Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells J. Biol. Chem., January 11, 2008; 283(2): 739 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lehnes, A. D. Winder, C. Alfonso, N. Kasid, M. Simoneaux, H. Summe, E. Morgan, M. C. Iann, J. Duncan, M. Eagan, et al. The Effect of Estradiol on in Vivo Tumorigenesis Is Modulated by the Human Epidermal Growth Factor Receptor 2/Phosphatidylinositol 3-Kinase/Akt1 Pathway Endocrinology, March 1, 2007; 148(3): 1171 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Foster, S. P. Newman, S. K. Chander, C. Stengel, R. Jhalli, L. L.W. Woo, B. V.L. Potter, M. J. Reed, and A. Purohit In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy. Clin. Cancer Res., September 15, 2006; 12(18): 5543 - 5549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kogai, Y. Kanamoto, L. H. Che, K. Taki, F. Moatamed, J. J. Schultz, and G. A. Brent Systemic Retinoic Acid Treatment Induces Sodium/Iodide Symporter Expression and Radioiodide Uptake in Mouse Breast Cancer Models Cancer Res., January 1, 2004; 64(1): 415 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Ju, C. D. Allred, K. F. Allred, K. L. Karko, D. R. Doerge, and W. G. Helferich Physiological Concentrations of Dietary Genistein Dose-Dependently Stimulate Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Athymic Nude Mice J. Nutr., November 1, 2001; 131(11): 2957 - 2962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oesterreich, P. Zhang, R. L. Guler, X. Sun, E. M. Curran, W. V. Welshons, C. K. Osborne, and A. V. Lee Re-expression of Estrogen Receptor {alpha} in Estrogen Receptor {alpha}-negative MCF-7 Cells Restores both Estrogen and Insulin-like Growth Factor-mediated Signaling and Growth Cancer Res., August 1, 2001; 61(15): 5771 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Allred, K. F. Allred, Y. H. Ju, S. M. Virant, and W. G. Helferich Soy Diets Containing Varying Amounts of Genistein Stimulate Growth of Estrogen-dependent (MCF-7) Tumors in a Dose-dependent Manner Cancer Res., July 1, 2001; 61(13): 5045 - 5050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. James, T. C. Skaar, R. Y. Lee, A. MacPherson, J. A. Zwiebel, B. S. Ahluwalia, F. Ampy, and R. Clarke Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cells in Vitro and in Vivo Endocrinology, April 1, 2001; 142(4): 1497 - 1505. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ochs, T. Stein, and E. Tan Coiled bodies in the nucleolus of breast cancer cells J. Cell Sci., January 2, 1994; 107(2): 385 - 399. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Dickson, M. McManaway, and M. Lippman Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth Science, June 20, 1986; 232(4757): 1540 - 1543. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
